Stock 688767 HANGZHOU BIOTEST BIOTECH CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Hangzhou Biotest Biotech Co.,Ltd.

Equities

688767

CNE1000050H0

Medical Equipment, Supplies & Distribution

End-of-day quote Shanghai S.E.
Other stock markets
 18:00:00 2024-05-23 EDT 		5-day change 1st Jan Change
28.53 CNY -1.52% Intraday chart for Hangzhou Biotest Biotech Co.,Ltd. -2.96% -5.75%
04-26 Hangzhou Biotest Biotech Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
02-23 Hangzhou Biotest Biotech Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2021 2022 2023
Capitalization 1 7,456 4,928 3,229
Enterprise Value (EV) 1 5,740 2,896 1,314
P/E ratio 7.27 x 6.37 x 30.3 x
Yield 4.29% 4.76% 2.64%
Capitalization / Revenue 4.1 x 2.59 x 7.3 x
EV / Revenue 3.16 x 1.52 x 2.97 x
EV / EBITDA 5.92 x 3.75 x 47.6 x
EV / FCF 12.9 x 10.4 x -71.8 x
FCF Yield 7.73% 9.66% -1.39%
Price to Book 3.54 x 1.92 x 1.33 x
Nbr of stocks (in thousands) 106,667 106,667 106,667
Reference price 2 69.90 46.20 30.27
Announcement Date 4/27/22 4/28/23 4/26/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 180.3 208.8 865.4 1,818 1,901 442.1
EBITDA 1 22.74 34.19 531.6 969 772.5 27.6
EBIT 1 18.61 29.35 526.2 961 752.7 3.701
Operating Margin 10.32% 14.05% 60.81% 52.86% 39.59% 0.84%
Earnings before Tax (EBT) 1 22.53 32.27 514.3 968.6 901.9 115.9
Net income 1 18.91 28.23 435.1 833.6 773.7 106.6
Net margin 10.49% 13.52% 50.28% 45.85% 40.69% 24.11%
EPS 2 0.2363 0.3500 5.439 9.620 7.250 1.000
Free Cash Flow 1 -0.6631 -15.79 283.1 443.5 279.6 -18.31
FCF margin -0.37% -7.56% 32.72% 24.39% 14.71% -4.14%
FCF Conversion (EBITDA) - - 53.27% 45.76% 36.2% -
FCF Conversion (Net income) - - 65.07% 53.2% 36.15% -
Dividend per Share - - - 3.000 2.200 0.8000
Announcement Date 10/12/20 10/12/20 4/22/21 4/27/22 4/28/23 4/26/24
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 3.76 18.3 - - - -
Net Cash position 1 - - 250 1,716 2,032 1,914
Leverage (Debt/EBITDA) 0.1652 x 0.5358 x - - - -
Free Cash Flow 1 -0.66 -15.8 283 443 280 -18.3
ROE (net income / shareholders' equity) 21.2% 24.9% 153% 65.5% 33.1% 4.23%
ROA (Net income/ Total Assets) 8.24% 10% 77.9% 39.2% 18.2% 0.09%
Assets 1 229.3 280.9 558.6 2,127 4,261 122,959
Book Value Per Share 2 1.240 1.590 5.550 19.80 24.00 22.70
Cash Flow per Share 2 0.2000 0.1700 3.260 12.80 18.20 18.00
Capex 1 12.7 39.5 57.7 200 179 56.4
Capex / Sales 7.03% 18.9% 6.67% 11.01% 9.41% 12.76%
Announcement Date 10/12/20 10/12/20 4/22/21 4/27/22 4/28/23 4/26/24
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Diagnostic & Testing Substances

1st Jan change Capi.
HANGZHOU BIOTEST BIOTECH CO.,LTD. Stock Hangzhou Biotest Biotech Co.,Ltd.
-5.75% 418M
BIOMÉRIEUX Stock bioMérieux
-4.92% 12.11B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD. Stock Shenzhen New Industries Biomedical Engineering Co., Ltd.
-5.82% 8.07B
DIASORIN S.P.A. Stock DiaSorin S.p.A.
+5.43% 5.67B
LANTHEUS HOLDINGS, INC. Stock Lantheus Holdings, Inc.
+26.16% 5.48B
AUTOBIO DIAGNOSTICS CO., LTD. Stock Autobio Diagnostics Co., Ltd.
-9.58% 4.12B
10X GENOMICS, INC. Stock 10x Genomics, Inc.
-59.63% 2.75B
ANDON HEALTH CO., LTD. Stock Andon Health Co., Ltd.
+8.44% 2.62B
VITROLIFE AB Stock Vitrolife AB
-3.70% 2.33B
MYRIAD GENETICS, INC. Stock Myriad Genetics, Inc.
+21.00% 2.11B
Diagnostic & Testing Substances
  1. Stock Market
  2. Equities
  3. 688767 Stock
  4. Financials Hangzhou Biotest Biotech Co.,Ltd.